活检确诊非酒精性脂肪性肝病患者的医疗费用几乎是匹配对照组的两倍
瑞典回顾性研究纳入646例活检确诊非酒精性脂肪性肝病(NAFLD)患者,按年龄、性别和居住县与10名普通人群对照匹配,随访至2014年底。平均随访19.9年,NAFLD患者年均住院0.27次 vs 对照0.16次(P < .001),年均门诊1.46次 vs 0.86次(P < .001)。NAFLD患者医疗总费用几乎是对照组的两倍,主要来自住院费用增加,纤维化3-4期患者费用最高。
要点
- NAFLD患者年均住院次数和门诊次数均显著高于匹配对照。
- NAFLD患者医疗总费用几乎是对照组的两倍。
- 纤维化3-4期患者年均费用最高。
核心结论
- NAFLD患者医疗费用几乎是对照组的两倍,主要归因于住院费用增加以及门诊次数增多。
- 纤维化3-4期患者的费用最高。
研究设计与样本
- 回顾性研究,纳入瑞典1971年至2009年646例活检确诊NAFLD患者,每例按年龄、性别和居住县与10名普通人群对照匹配。
主要发现
- 平均随访19.9年期间,NAFLD患者年均住院0.27次,对照组0.16次(P < .001),对应NAFLD患者每年额外费用635美元。
- NAFLD患者年均门诊就诊1.46次,对照组0.86次(P < .001),对应额外费用255美元。
- 纤维化3-4期患者年均费用为4397美元,纤维化0-2期患者为629美元。
- 所有纤维化分期患者的累积费用均高于对照组。
临床怎么用
- 临床实践中应关注NAFLD患者的医疗资源使用,尤其是住院和门诊费用负担。
- 对纤维化3-4期患者应加强管理,因其医疗费用最高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Data on healthcare resource use and costs associated with nonalcoholic fatty liver disease (NAFLD) in clinical practice are lacking. We compared real-life healthcare costs of patients with NAFLD to matched controls. METHODS: We performed a retrospective study of 646 patients with biopsy-proven NAFLD in Sweden from 1971 through 2009. Each patient was matched for age, sex, and county of residence with 10 persons from the general population (controls). We retrieved all healthcare contacts through Dec 31, 2014 from national registers. Unit costs were assigned to arrive at a total healthcare cost (in USD [$]) per study subject. RESULTS: During a mean follow-up of 19.9 years, we recorded a mean of 0.27 hospitalizations per year for patients with NAFLD vs 0.16 for controls (P < .001). This corresponded to an incremental cost of $635 per year for patients with NAFLD. Patients with NAFLD had a higher mean use of outpatient care visits: 1.46 contacts per year compared with 0.86 per year in controls, corresponding to $255 in additional costs (P < .001). Total costs incurred by patients with stage 3-4 fibrosis were higher than by patients with fibrosis stage 0-2 (mean annual costs, $4397 vs $629). Cumulative costs were higher for all stages of fibrosis compared to controls. CONCLUSIONS: Healthcare costs are nearly twice as high in patients with NAFLD than in matched controls. This is mostly attributable to higher costs for hospitalizations, but also to more outpatient visits. Patients with advanced fibrosis had the highest costs.
引用
- Hagström H, Nasr P, Ekstedt M, et al. Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. Clin Gastroenterol Hepatol. 2019. PMID: 31634581. doi:10.1016/j.cgh.2019.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。